Alendronate Sodium Hydrate

Alendronate, also known as Fosamax, is an inhibitor of farnesyl diphosphate synthase, with an IC50 of 460 nM. This nitrogen-containing bisphosphate is highly effective at inhibiting bone resorption and inducing apoptosis in osteoclasts. Through its ability to disrupt the ruffled border and actin cytoskeleton of osteoclasts, Alendronate has been shown to induce in vitro apoptosis of osteoclasts and macrophages. Additionally, this compound has been found to act as a broad-spectrum MMP inhibitor with an IC50 of approximately 40-70 μM. Alendronate displays a strong ability to chelate metal ions, and also exhibits antimetastatic, anti-invasive, and cell-adhesion-promoting properties, with an IC50 of approximately 1 pM in vitro invasion of prostate cancer cells.

>98%

store at -20° C for one year（Powder）；
To maximize the shelf life of your product, it is recommended to store it in DMSO or other suitable solvents at a temperature range of 2-4° C for two weeks. If longer-term storage is required, it is advised to keep it at -20° C for a period of up to six months. These storage conditions will help to maintain the stability and integrity of your product over time, ensuring that it remains fully functional and effective when you need it most. By following these guidelines, you can rest assured that your product will be in optimal condition and ready to use whenever you need it.

G-704650 Adronat

DMSO ：20 mg/mL (61.3 mM) with gentle warming

Water ：20 mg/mL (61.3 mM) with gentle warming

Alendronate works directly on osteoclasts by blocking a crucial step in the cholesterol biosynthesis process, which is necessary for osteoclast function. By inhibiting the isoprenoid biosynthesis pathway, alendronate disrupts protein prenylation through a decrease in the levels of geranylgeranyl diphosphate. Specifically, alendronate prevents the incorporation of mevalonolactone into 18-25 kDa proteins and sterols in osteoclasts, as well as into nonsaponifiable lipids. This medication has been shown to significantly decrease MVA incorporation into sterols while increasing radiolabel incorporation into IPP and DMAPP in a dose-dependent manner.

Alendronate causes erosions in the rabbit stomach, but not antral ulceration in rats. Alendronate increases the incidence and size of indomethacin-induced antral ulcers. Alendronate also enhances indomethacin-induced gastricdamage in the rat, and delayed gastric ulcer healing.  Alendronate (0.04-0.1 mg/kg twice weekly or 0.1 mg/kg weekly) partially blocks the establishment of bone metastases by human PC-3 ML cells and results in tumor formation in the peritoneum and other soft tissues. Alendronate pretreatment of mice (0.1 mg/kg twice weekly or weekly) and dosing along with taxol (10-50 mg/kg/day, twice weekly, or weekly) blocks the growth of PC-3 ML tumors in the bone marrow and soft tissues in a statistically significant manner and improves survival rates significantly by 4-5 weeks.